Cargando…

Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost

AIM: In the treatment of prostate cancer with radiation therapy, the addition of a simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL) may improve local control. In this study, we aimed to determine the optimal radiation strategy in a phantom model of prostate cancer usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Skrobala, Agnieszka, Kruszyna-Mochalska, Marta, Graczyk, Kinga, Ryczkowski, Adam, Fundowicz, Magdalena, Milecki, Piotr, Malicki, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175813/
https://www.ncbi.nlm.nih.gov/pubmed/37188175
http://dx.doi.org/10.3389/fonc.2023.1147593
_version_ 1785040293705285632
author Skrobala, Agnieszka
Kruszyna-Mochalska, Marta
Graczyk, Kinga
Ryczkowski, Adam
Fundowicz, Magdalena
Milecki, Piotr
Malicki, Julian
author_facet Skrobala, Agnieszka
Kruszyna-Mochalska, Marta
Graczyk, Kinga
Ryczkowski, Adam
Fundowicz, Magdalena
Milecki, Piotr
Malicki, Julian
author_sort Skrobala, Agnieszka
collection PubMed
description AIM: In the treatment of prostate cancer with radiation therapy, the addition of a simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL) may improve local control. In this study, we aimed to determine the optimal radiation strategy in a phantom model of prostate cancer using volumetric modulated arc therapy for stereotactic body radiotherapy (SBRT-VMAT) with a SIB of 1-4 DILs. METHODS: We designed and printed a three-dimensional anthropomorphic phantom pelvis to simulate individual patient structures, including the prostate gland. A total of 36.25 Gy (SBRT) was delivered to the whole prostate. The DILs were irradiated with four different doses (40, 45, 47.5, and 50 Gy) to assess the influence of different SIB doses on dose distribution. The doses were calculated, verified, and measured using both transit and non-transit dosimetry for patient-specific quality assurance using a phantom model. RESULTS: The dose coverage met protocol requirements for all targets. However, the dose was close to violating risk constraints to the rectum when four DILs were treated simultaneously or when the DILs were located in the posterior segments of the prostate. All verification plans passed the assumed tolerance criteria. CONCLUSIONS: Moderate dose escalation up to 45 Gy seems appropriate in cases with DILs located in posterior prostate segments or if there are three or more DILs located in other segments.
format Online
Article
Text
id pubmed-10175813
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101758132023-05-13 Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost Skrobala, Agnieszka Kruszyna-Mochalska, Marta Graczyk, Kinga Ryczkowski, Adam Fundowicz, Magdalena Milecki, Piotr Malicki, Julian Front Oncol Oncology AIM: In the treatment of prostate cancer with radiation therapy, the addition of a simultaneous integrated boost (SIB) to the dominant intraprostatic lesions (DIL) may improve local control. In this study, we aimed to determine the optimal radiation strategy in a phantom model of prostate cancer using volumetric modulated arc therapy for stereotactic body radiotherapy (SBRT-VMAT) with a SIB of 1-4 DILs. METHODS: We designed and printed a three-dimensional anthropomorphic phantom pelvis to simulate individual patient structures, including the prostate gland. A total of 36.25 Gy (SBRT) was delivered to the whole prostate. The DILs were irradiated with four different doses (40, 45, 47.5, and 50 Gy) to assess the influence of different SIB doses on dose distribution. The doses were calculated, verified, and measured using both transit and non-transit dosimetry for patient-specific quality assurance using a phantom model. RESULTS: The dose coverage met protocol requirements for all targets. However, the dose was close to violating risk constraints to the rectum when four DILs were treated simultaneously or when the DILs were located in the posterior segments of the prostate. All verification plans passed the assumed tolerance criteria. CONCLUSIONS: Moderate dose escalation up to 45 Gy seems appropriate in cases with DILs located in posterior prostate segments or if there are three or more DILs located in other segments. Frontiers Media S.A. 2023-04-28 /pmc/articles/PMC10175813/ /pubmed/37188175 http://dx.doi.org/10.3389/fonc.2023.1147593 Text en Copyright © 2023 Skrobala, Kruszyna-Mochalska, Graczyk, Ryczkowski, Fundowicz, Milecki and Malicki https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Skrobala, Agnieszka
Kruszyna-Mochalska, Marta
Graczyk, Kinga
Ryczkowski, Adam
Fundowicz, Magdalena
Milecki, Piotr
Malicki, Julian
Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
title Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
title_full Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
title_fullStr Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
title_full_unstemmed Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
title_short Radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
title_sort radiotherapy planning in a prostate cancer phantom model with intraprostatic dominant lesions using stereotactic body radiotherapy with volumetric modulated arcs and a simultaneous integrated boost
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175813/
https://www.ncbi.nlm.nih.gov/pubmed/37188175
http://dx.doi.org/10.3389/fonc.2023.1147593
work_keys_str_mv AT skrobalaagnieszka radiotherapyplanninginaprostatecancerphantommodelwithintraprostaticdominantlesionsusingstereotacticbodyradiotherapywithvolumetricmodulatedarcsandasimultaneousintegratedboost
AT kruszynamochalskamarta radiotherapyplanninginaprostatecancerphantommodelwithintraprostaticdominantlesionsusingstereotacticbodyradiotherapywithvolumetricmodulatedarcsandasimultaneousintegratedboost
AT graczykkinga radiotherapyplanninginaprostatecancerphantommodelwithintraprostaticdominantlesionsusingstereotacticbodyradiotherapywithvolumetricmodulatedarcsandasimultaneousintegratedboost
AT ryczkowskiadam radiotherapyplanninginaprostatecancerphantommodelwithintraprostaticdominantlesionsusingstereotacticbodyradiotherapywithvolumetricmodulatedarcsandasimultaneousintegratedboost
AT fundowiczmagdalena radiotherapyplanninginaprostatecancerphantommodelwithintraprostaticdominantlesionsusingstereotacticbodyradiotherapywithvolumetricmodulatedarcsandasimultaneousintegratedboost
AT mileckipiotr radiotherapyplanninginaprostatecancerphantommodelwithintraprostaticdominantlesionsusingstereotacticbodyradiotherapywithvolumetricmodulatedarcsandasimultaneousintegratedboost
AT malickijulian radiotherapyplanninginaprostatecancerphantommodelwithintraprostaticdominantlesionsusingstereotacticbodyradiotherapywithvolumetricmodulatedarcsandasimultaneousintegratedboost